Cargando…

Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study

BACKGROUND: Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tun, Kyaw Myo, Jeeyapant, Atthanee, Imwong, Mallika, Thein, Min, Aung, Sai Soe Moe, Hlaing, Tin Maung, Yuentrakul, Prayoon, Promnarate, Cholrawee, Dhorda, Mehul, Woodrow, Charles J., Dondorp, Arjen M., Ashley, Elizabeth A., Smithuis, Frank M., White, Nicholas J., Day, Nicholas P. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815199/
https://www.ncbi.nlm.nih.gov/pubmed/27036739
http://dx.doi.org/10.1186/s12936-016-1240-7
_version_ 1782424560659857408
author Tun, Kyaw Myo
Jeeyapant, Atthanee
Imwong, Mallika
Thein, Min
Aung, Sai Soe Moe
Hlaing, Tin Maung
Yuentrakul, Prayoon
Promnarate, Cholrawee
Dhorda, Mehul
Woodrow, Charles J.
Dondorp, Arjen M.
Ashley, Elizabeth A.
Smithuis, Frank M.
White, Nicholas J.
Day, Nicholas P. J.
author_facet Tun, Kyaw Myo
Jeeyapant, Atthanee
Imwong, Mallika
Thein, Min
Aung, Sai Soe Moe
Hlaing, Tin Maung
Yuentrakul, Prayoon
Promnarate, Cholrawee
Dhorda, Mehul
Woodrow, Charles J.
Dondorp, Arjen M.
Ashley, Elizabeth A.
Smithuis, Frank M.
White, Nicholas J.
Day, Nicholas P. J.
author_sort Tun, Kyaw Myo
collection PubMed
description BACKGROUND: Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of preventive and curative treatment in the region, but its therapeutic efficacy has fallen in Cambodia. METHODS: A prospective clinical and parasitological evaluation of DP was conducted at two sites in Upper Myanmar between August 2013 and December 2014, enrolling 116 patients with acute uncomplicated falciparum malaria. Patients received DP orally for 3 days together with primaquine 0.25 mg/kg on admission. Parasite clearance half-lives based on 6 hourly blood smears, and day 42 therapeutic responses were assessed as well as parasite K13 genotypes. RESULTS: Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21 % of patients. Delayed parasite clearance was significantly associated with mutations in the propeller region of the parasite k13 gene. The k13 F446I mutation was found in 25.4 % of infections and was associated with a median clearance half-life of 4.7 h compared with 2.7 h for infections without k13 mutations (p < 0.001). There were no failures after 42 days of follow-up, although 18 % of patients had persistent parasitaemia on day 3. CONCLUSION: The dominant k13 mutation observed in Upper Myanmar, F446I, appears to be associated with an intermediate rate of parasite clearance compared to other common mutations described elsewhere in the Greater Mekong Subregion. Discerning this phenotype requires relatively detailed clearance measurements, highlighting the importance of methodology in assessing artemisinin resistance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1240-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4815199
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48151992016-04-01 Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study Tun, Kyaw Myo Jeeyapant, Atthanee Imwong, Mallika Thein, Min Aung, Sai Soe Moe Hlaing, Tin Maung Yuentrakul, Prayoon Promnarate, Cholrawee Dhorda, Mehul Woodrow, Charles J. Dondorp, Arjen M. Ashley, Elizabeth A. Smithuis, Frank M. White, Nicholas J. Day, Nicholas P. J. Malar J Research BACKGROUND: Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of preventive and curative treatment in the region, but its therapeutic efficacy has fallen in Cambodia. METHODS: A prospective clinical and parasitological evaluation of DP was conducted at two sites in Upper Myanmar between August 2013 and December 2014, enrolling 116 patients with acute uncomplicated falciparum malaria. Patients received DP orally for 3 days together with primaquine 0.25 mg/kg on admission. Parasite clearance half-lives based on 6 hourly blood smears, and day 42 therapeutic responses were assessed as well as parasite K13 genotypes. RESULTS: Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21 % of patients. Delayed parasite clearance was significantly associated with mutations in the propeller region of the parasite k13 gene. The k13 F446I mutation was found in 25.4 % of infections and was associated with a median clearance half-life of 4.7 h compared with 2.7 h for infections without k13 mutations (p < 0.001). There were no failures after 42 days of follow-up, although 18 % of patients had persistent parasitaemia on day 3. CONCLUSION: The dominant k13 mutation observed in Upper Myanmar, F446I, appears to be associated with an intermediate rate of parasite clearance compared to other common mutations described elsewhere in the Greater Mekong Subregion. Discerning this phenotype requires relatively detailed clearance measurements, highlighting the importance of methodology in assessing artemisinin resistance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1240-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-31 /pmc/articles/PMC4815199/ /pubmed/27036739 http://dx.doi.org/10.1186/s12936-016-1240-7 Text en © Tun et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tun, Kyaw Myo
Jeeyapant, Atthanee
Imwong, Mallika
Thein, Min
Aung, Sai Soe Moe
Hlaing, Tin Maung
Yuentrakul, Prayoon
Promnarate, Cholrawee
Dhorda, Mehul
Woodrow, Charles J.
Dondorp, Arjen M.
Ashley, Elizabeth A.
Smithuis, Frank M.
White, Nicholas J.
Day, Nicholas P. J.
Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
title Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
title_full Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
title_fullStr Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
title_full_unstemmed Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
title_short Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
title_sort parasite clearance rates in upper myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815199/
https://www.ncbi.nlm.nih.gov/pubmed/27036739
http://dx.doi.org/10.1186/s12936-016-1240-7
work_keys_str_mv AT tunkyawmyo parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT jeeyapantatthanee parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT imwongmallika parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT theinmin parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT aungsaisoemoe parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT hlaingtinmaung parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT yuentrakulprayoon parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT promnaratecholrawee parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT dhordamehul parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT woodrowcharlesj parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT dondorparjenm parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT ashleyelizabetha parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT smithuisfrankm parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT whitenicholasj parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy
AT daynicholaspj parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy